SCHEMBL688290

SCHEMBL688290

IC=P(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.43
CA2 P00918 1/20 0.38
CA4 P22748 1/20 0.38
CA5A P35218 1/20 0.38
ALOX15 P16050 2/20 0.36
TSHR P16473 2/20 0.36
USP2 O75604 1/20 0.36
ESR1 P03372 3/20 0.33
ESR2 Q92731 2/20 0.33
CFTR P13569 1/20 0.33
GAA P10253 3/20 0.32
L3MBTL1 Q9Y468 3/20 0.32
ALDH1A1 P00352 3/20 0.32
TDP1 Q9NUW8 2/20 0.32
ALOX12 P18054 2/20 0.32
MAPT P10636 2/20 0.32
NPSR1 Q6W5P4 2/20 0.32
ALPG P10696 1/20 0.32
NPY1R P25929 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL868072 0.77 HSP90AA1 (0.39) HSP90AA1CA2CA4CA5AALOX15
Bromide SCHEMBL5063713 0.74 HSP90AA1 (0.38) HSP90AA1CA2CA4CA5AALOX15
SCHEMBL6397176 0.71 HSP90AA1 (0.43) HSP90AA1CA2CA4CA5AALOX15
SCHEMBL4968872 0.71 CA2 (0.43) HSP90AA1CA2CA4CA5AALOX15
SCHEMBL10176540 0.71 HSP90AA1 (0.39) HSP90AA1CA2CA4CA5AALOX15
SCHEMBL7633171 0.71 HSP90AA1 (0.39) HSP90AA1CA2CA4CA5AALOX15
SCHEMBL306807 0.71 TSHR (0.41) HSP90AA1CA2CA4CA5AALOX15
SCHEMBL3140190 0.71 HSP90AA1 (0.39) HSP90AA1CA2CA4CA5AALOX15
SCHEMBL814 0.70 HSP90AA1 (0.59) HSP90AA1CA2CA4CA5AALOX15
SCHEMBL7096547 0.70 ALDH1A1 (0.36) HSP90AA1CA2CA4CA5AALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4419513-B1 ANTITUMORAL COMPOUNDS PHARMA MAR SA (ES) 2025-08-27 EP disclosed
US-20250243174-A1 ANTITUMORAL COMPOUNDS PHARMA MAR, S.A. (ES) 2025-07-31 US disclosed
EP-4419513-A1 ANTITUMORAL COMPOUNDS Pharma Mar S.A. (ES) 2024-08-28 EP disclosed
CN-118139851-A Antitumor compounds 法马马有限公司 2024-06-04 CN disclosed
WO-2023067132-A1 ANTITUMORAL COMPOUNDS PHARMA MAR, S.A. (ES) 2023-04-27 WO disclosed
US-8263598-B2 Substituted sulfonamide compounds GRUENENTHAL GMBH (DE) 2012-09-11 US disclosed
US-8178535-B2 Substituted sulfonamide compounds having bradykinin 1 receptor activity and use thereof as medicaments GRUENENTHAL GMBH (DE) 2012-05-15 US disclosed
EP-1606248-B1 SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE SPA (IT) 2012-02-29 EP disclosed
US-7737139-B2 Sulfonic acids, their derivatives and pharmaceutical compositions containing them DOMPE PHA.R.MA S.P.A. (IT) 2010-06-15 US disclosed
US-20090203672-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2009-08-13 US disclosed
US-20090186899-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2009-07-23 US disclosed
US-20060258730-A1 Sulfonic acids, their derivatives and pharmaceutical compositions containing them DOMPE S.P.A. (IT) 2006-11-16 US disclosed
EP-1606248-A2 SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Dompé S.P.A. (IT) 2005-12-21 EP disclosed
WO-2004080951-A2 SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE S.P.A. (IT) 2004-09-23 WO disclosed
EP-1457485-A1 Sulfonic acids, their derivatives and pharmaceutical compositions containing them Dompé S.P.A. (IT) 2004-09-15 EP disclosed
US-20040018598-A1 Bio-intermediates for use in the chemical synthesis of polyketides SANTI DANIEL (US) 2004-01-29 US disclosed
EP-1307579-A2 BIO-INTERMEDIATES FOR USE IN THE CHEMICAL SYNTHESIS OF POLYKETIDES Kosan Biosciences, Inc. (US) 2003-05-07 EP disclosed
US-20020052028-A1 Bio-intermediates for use in the chemical synthesis of polyketides KOSAN BIOSCIENCES, INC. 2002-05-02 US disclosed
WO-2002012534-A2 BIO-INTERMEDIATES FOR USE IN THE CHEMICAL SYNTHESIS OF POLYKETIDES KOSAN BIOSCIENCES, INC. (US) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250243174-A1 ANTITUMORAL COMPOUNDS MCL1, XPOT, GZMB HSP90AA1 1320/4885CA2 2208/4885CA4 366/4885
US-20090186899-A1 Substituted Sulfonamide Compounds BDKRB1, BDKRB2, NPSR1 HSP90AA1 3101/4885CA2 592/4885CA4 1558/4885
US-20040018598-A1 Bio-intermediates for use in the chemical synthesis of polyketides DHPS, FDFT1, COASY HSP90AA1 4177/4885CA2 4856/4885CA4 4242/4885
US-20090203672-A1 Substituted Sulfonamide Compounds RPS4X, RPS4Y1, CACNA1A HSP90AA1 2875/4885CA2 806/4885CA4 710/4885
US-20060258730-A1 Sulfonic acids, their derivatives and pharmaceutical compositions containing them CCR8, CCR1, CXCR1 HSP90AA1 2641/4885CA2 565/4885CA4 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.